Hainan Shuangcheng Pharmaceuticals Co., Ltd.: history, ownership, mission, how it works & makes money

Founded in May 2000, Hainan Shuangcheng Pharmaceuticals Co., Ltd. (listed 002693.SZ) has grown from a peptide-focused developer into a vertically integrated maker of APIs and finished drugs-backed by a US$8 million investment from SEAVI Advent in August 2010-and today operates R&D and production sites in Haikou (Haikou facility approved in October 2025) and Ningbo (about 1.5 hours from Shanghai Pudong) plus an Italian subsidiary, serving clinics, hospitals and international markets with products cleared by the U.S. FDA and AIFA; the company reported a narrowed nine-month net loss of CNY 2.52 million (to Sept. 30, 2025) versus CNY 37.84 million a year earlier, maintains a registered capital of CNY 416.79 million, completed a repurchase cancelling 2,100,000 restricted shares (total shares now 414,689,750 as of Aug. 15, 2024), employs roughly 605 people, and as of Dec. 18, 2025 traded at CNY 6.58 with a market capitalization of CNY 2.74 billion while pursuing CDMO growth, oncology and infectious-disease pipelines, and a sharpened focus on core operations after canceling the Hangzhou Aopeng acquisition in March 2025

Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ): Intro

• Founded in May 2000, Hainan Shuangcheng Pharmaceuticals Co., Ltd. is a publicly traded company focused on development, manufacturing and marketing of active pharmaceutical ingredients (APIs) and finished drug products, with a strong emphasis on peptide-based pharmaceuticals.
• August 2010: SEAVI Advent Private Equity invested US$8 million, citing the company's leadership in peptides and its extensive product portfolio.
• March 2025: The company cancelled a previously announced acquisition of Hangzhou Aopeng Investment Management Co., Ltd., signaling a strategic refocus on core operations.
• October 2025: Received approval from the Hainan Provincial Drug Administration for its Haikou facility, expanding production capacity and regulatory compliance for local manufacturing.
• November 2025: Reported improved operating performance-net loss of CNY 2.52 million for the nine months ended September 30, 2025, versus a net loss of CNY 37.84 million in the same period of the prior year.

• Publicly listed on the Shenzhen Stock Exchange (ticker: 002693.SZ).
• Notable historical private-equity backing: SEAVI Advent Private Equity (US$8 million, 2010).
• As of December 18, 2025: market capitalization approximately CNY 2.74 billion; share price CNY 6.58.

• Mission: to develop and commercially produce high-quality APIs and finished pharmaceuticals, with specialization in peptide therapeutics and niche APIs for domestic and export markets.
• Strategic priorities: strengthen core manufacturing, maintain regulatory compliance (e.g., Haikou facility approval), optimize product mix toward higher-margin APIs and formulations, and concentrate investment on organic growth rather than non-core M&A after the March 2025 cancellation.

• R&D: peptide chemistry, API synthesis, formulation development for finished dosage forms.
• Manufacturing: licensed API and finished-product production at approved facilities (including Haikou facility approval in Oct 2025).
• Sales & Distribution: domestic hospital and retail channels, partnerships for export markets; revenue streams from API sales, finished drugs and contract manufacturing.
• Regulatory & Quality: adherence to provincial/ national drug administration standards; facility approvals key to capacity utilization.

• Peptide-based APIs and related finished dosage forms.
• Generic small-molecule APIs and standard formulations for chronic and acute indications.
• Contract manufacturing services leveraging newly approved production capacity.

Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ): History

• Listing: Shenzhen Stock Exchange, ticker 002693.SZ.
• Registered capital: CNY 416.79 million.
• Equity adjustment: On August 15, 2024 the company completed repurchase and cancellation of 2,100,000 restricted shares, reducing total share capital to 414,689,750 shares.
• Ownership composition: A mix of institutional investors and individual shareholders, with a controlling shareholder holding the largest block and guiding strategic decisions.
• Actual controller: Wang Chengdong, who holds a substantial share stake and exerts material influence on corporate governance and strategy.

• How ownership affects operations: The controlling shareholder and actual controller steer capital allocation, M&A moves, and executive appointments-key levers for a publicly traded pharma company navigating regulatory, R&D and market expansion demands.
• Capital structure implications: Registered capital and recent share cancellations slightly tighten floating supply; detailed shareholding percentages and institutional holdings shift over quarterly disclosures.

Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ): Ownership Structure

• Mission and Values: committed to delivering high-quality pharmaceutical solutions with an emphasis on peptide chemistry innovation and patient-centric therapeutics.
• Quality and Compliance: manufactures to international standards; products approved for use by regulators including the U.S. FDA and the Italian Medicines Agency (AIFA) in relevant submissions and permissions.
• R&D and Collaboration: maintains active collaborations with recognized medical institutions and research centers to advance new peptide drugs and improved formulations.
• Integrity and Transparency: adheres to regulatory requirements, corporate governance practices, and disclosure norms to maintain stakeholder trust.
• Global Expansion: actively seeks partnerships and licensing deals across the U.S., Europe and other regions to broaden commercial reach.
• Patient Focus: prioritizes development of drugs addressing infectious diseases and chronic conditions with an emphasis on safety and efficacy.

• Largest shareholder: Hainan Shuangcheng Group (state-affiliated investor) - controlling stake and board influence.
• Institutional investors: mixture of domestic funds and strategic pharmaceutical partners holding significant minority positions.
• Management & insiders: executives and senior researchers hold a combined minority stake aligned with long-term incentive programs.

• Peptide APIs: manufacture and sale of high-purity peptide active pharmaceutical ingredients to domestic and international pharmaceutical firms.
• Finished formulations: development and commercialization of peptide-based finished drugs for therapeutic use.
• Contract manufacturing & R&D services: fee-based custom synthesis, process development and clinical supply for partners.
• Licensing & partnerships: milestone and royalty income from co-development and licensing deals with overseas firms.

• Vertical integration: in-house peptide synthesis platforms, QC, and formulation capabilities reduce time-to-market and unit costs.
• Regulatory footprint: experience with FDA and AIFA pathways supports exportable product dossiers and GMP compliance.
• R&D pipeline: focus on infectious disease peptides and chronic-disease therapeutics supported by institutional collaborations.
• Cost structure: scale in peptide manufacturing and process optimization helps preserve margins despite high R&D intensity.

Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ): Mission and Values

• Headquarters: No. 16 Xingguo Road, Haikou, Hainan Province, China - centralized management and corporate functions.
• R&D focus: peptide chemistry and pharmaceutical innovations at the Haikou site, with dedicated research teams and laboratories.
• International presence: subsidiary Shuangcheng Pharmaceuticals Europe S.r.l. in Italy to support European market access and regulatory engagement.
• Manufacturing footprint: production facility in Ningbo (about 1.5 hours' drive from Shanghai Pudong Airport) to expand capacity and optimize logistics for domestic and export shipments.
• Workforce: approximately 605 employees across R&D, production, quality control, regulatory affairs, and corporate administration.
• Service model: offers CDMO (contract development and manufacturing organization) services, providing end‑to‑end solutions from process development to commercial manufacturing for external pharma clients.

• Centralized strategy and governance from Haikou ensure consistent quality, regulatory compliance, and strategic allocation of R&D and CAPEX.
• R&D pipeline and peptide expertise drive value through proprietary projects, out‑licensing opportunities, and fee‑based CDMO projects.
• CDMO services generate recurring contract revenue by supporting third‑party drug candidates at various development stages (process R&D, GMP clinical supply, tech transfer, commercial production).
• Manufacturing in Ningbo provides scalable GMP capacity to accommodate both domestic supply and export orders, reducing lead times for international clients.
• European subsidiary enables local regulatory support, business development, and logistics coordination for EU market entry and client services.

• Peptide synthesis and optimization for therapeutics and APIs.
• Analytical method development, stability studies, and quality assurance consistent with GMP requirements.
• Process development and scale‑up enabling transition from lab to commercial batches.
• End‑to‑end CDMO offerings: discovery support, IND‑enabling manufacturing, clinical and commercial production contracts.
• Cross‑border support via the Italian subsidiary for regulatory filings and EU market entry.

Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ): How It Works

• Primary business lines: APIs, finished drugs (oral solids, injectables), and CDMO/custom manufacturing.
• Sales channels: direct distribution to hospitals and clinics, provincial distributors, international wholesalers and institutional tenders.
• Geographic reach: domestic China market plus exports to regulated markets after securing approvals (e.g., U.S. FDA, AIFA) and other international markets.

• Product sales: commercial sales of APIs and finished pharmaceutical products to hospitals, clinics and distributors across China.
• CDMO services: fee-for-service revenue from formulation development, scale-up and commercial manufacturing for third-party pharma companies.
• Exports and international tenders: revenues from products approved for overseas markets, leveraging regulatory clearances to access higher-value contracts.
• R&D-driven product launches: revenue growth from patented or newly registered products targeted at oncology and infectious disease segments.

• API sales: stable base revenue; commodity and high-margin complex APIs for oncology and antivirals.
• Finished products: branded generics and hospital-focused sterile/injectable products sold through tender and direct-sales models.
• CDMO: rising contribution from third-party contracts - development fees, registration-related milestone payments, and ongoing manufacturing contracts.

• Domestic hospital channel: direct sales teams and provincial distributors target tertiary and secondary hospitals; institutional tenders for large-volume contracts.
• Regional distributors: manage reach into county-level hospitals, clinics and retail pharmacies where applicable.
• International exports: regulatory approvals (e.g., U.S. FDA, AIFA) enable placement with overseas wholesalers and participation in international tenders.

• R&D investments target formulation upgrades, bioequivalence studies for generics, and development of specialty oncology and anti-infective agents to capture higher margins.
• Regulatory approvals expand addressable markets; a single approval (e.g., FDA) can materially boost per-unit pricing and open institutional sales channels abroad.
• CDMO engagements provide near-term, lower-risk revenue while pipeline assets progress through registration.

• Revenue diversification: product sales (APIs + finished drugs) remain core; CDMO and exports drive incremental growth and margin expansion.
• Margin leverage: new specialty product launches and export approvals are the primary levers to improve gross and net margins over time.
• Cash generation: stable operating cash flow from recurring hospital contracts supports continued R&D and capacity expansion.

Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ): How It Makes Money

• Core revenue streams: sales of proprietary peptide drugs, API/CMC contract manufacturing, licensing/royalty income and service contracts with overseas partners.
• Geographic revenue mix: domestic China sales plus growing export revenue following approvals from the U.S. FDA and Italy's AIFA for selected products.
• R&D-driven product pipeline monetization: clinical milestones, new drug approvals, and lifecycle extension of existing peptides.

• Peptide leadership: Hainan Shuangcheng occupies a specialist niche in peptide therapeutics in China, estimated market share within the peptide-based drug segment of mid-single digits domestically, with outsized expertise in synthesis and formulation.
• International expansion: FDA and AIFA approvals facilitate entry to higher-margin developed markets; establishment of an Italian subsidiary and expanded Ningbo manufacturing capacity are concrete steps to support export supply chains and registration activities in Europe and North America.
• 2025 financials & corrective actions: despite a reported net loss in 2025 (RMB 120 million), the company is pursuing cost optimization, higher-margin product mix, and licensing deals aimed at restoring profitability by improving gross margins and reducing fixed-cost intensity.
• R&D & pipeline: ongoing investment (~RMB 150-180 million/year) targets first-in-class or best-in-class peptide candidates for unmet medical needs; partnerships with contract research organizations and academic collaborators accelerate clinical progress.
• Quality & compliance focus: GMP upgrades in Ningbo and international regulatory approvals signal strong compliance posture, a prerequisite for larger volume contracts with multinational pharma and for tender access in regulated markets.

• Scale manufacturing in Ningbo to capture contract manufacturing orders and lower unit costs.
• Leverage the Italian subsidiary for EU regulatory filings, local clinical support, and business development.
• Pursue out-licensing and milestone/royalty agreements in the U.S. and Europe to accelerate cash inflows while sharing commercialization risk.
• Prioritize high-margin specialty peptide products and lifecycle management to improve operating leverage.